Clinical TrialJul 22, 2026, 08:02 AM
LB Pharma Accelerates Phase 3 Schizophrenia Trial Results to H1 2027
AI Summary
LB Pharmaceuticals announced an accelerated timeline for its pivotal Phase 3 NOVA-2 clinical trial of LB-102 for schizophrenia, with topline results now expected in the first half of 2027, earlier than the previously guided second half of 2027. Following this, a pre-NDA meeting with the FDA is anticipated in the second half of 2027. The company also provided updates on other trials, expecting Phase 2 data for bipolar depression in Q1 2028 and for adjunctive MDD in H1 2029, while maintaining a cash runway into Q2 2029.
Key Highlights
- Topline results for pivotal Phase 3 NOVA-2 trial (schizophrenia) now expected in H1 2027, ahead of prior H2 2027 guidance.
- Pre-NDA meeting with the FDA for LB-102 anticipated in H2 2027.
- Phase 3 NOVA-2 trial is designed to enroll approximately 460 patients across 25 U.S. sites.
- Topline data from Phase 2 ILLUMINATE-1 trial (bipolar depression) expected in Q1 2028.
- Topline data from Phase 2 trial (adjunctive MDD) expected in H1 2029.
- Company is well-capitalized with a cash runway expected to fund operations into Q2 2029.
Price Impact
More from LBRX